What Is Claimed Is:

1. Use of pirfenidone in the manufacture of a medicament for treating a patient in need of pirfenidone therapy, characterized in that the treating comprises (a) avoiding, contraindicating or discontinuing concomitant use or co-administration of a cytochrome P450 1A2 (CYP1A2) inhibitor that is a moderate to strong inhibitor of both (i) cytochrome P450 1A2 (CYP1A2) and (ii) another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19, CYP2D6 and/or CYP2E1 in a patient receiving pirfenidone, or (b) avoiding, contraindicating, or discontinuing a strong CYP1A2 inhibitor in a patient receiving pirfenidone, or (c) avoiding, contraindicating, or discontinuing a CYP1A2 inhibitor selected from the group consisting of fluvoxamine, enoxacin, ciprofloxacin, amiodarone and propafenone in a patient receiving pirfenidone, or (d) reducing the dose of pirfenidone in patients receiving a strong inhibitor of CYP1A2, wherein the patient is in need of therapy with a CYP1A2 inhibitor.

2. The use of claim 1 wherein the CYP1A2 inhibitor is a moderate to strong inhibitor of CYP1A2 and another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19, CYP2D6 and/or CYP2E1.

3. The use of claim 1 wherein the CYP1A2 inhibitor is a strong CYP1A2 inhibitor.

4. The use of any of claims 1-3 wherein the CYP1A2 inhibitor is discontinued prior to starting pirfenidone therapy to avoid an adverse drug interaction with pirfenidone, or to avoid a reduced clearance of pirfenidone.

5. The use of any one of claims 1-4 wherein the CYP1A2 inhibitor is discontinued within 1 month prior to starting pirfenidone therapy.

6. The use of any one of claims 1-5 wherein the CYP1A2 inhibitor is discontinued within 2 weeks prior to starting pirfenidone therapy.

7. The use of any of claims 1-3 wherein the CYP1A2 inhibitor is avoided during pirfenidone therapy.

8. The use of any of claims 1-3 wherein the patient is suffering from a fibrotic condition.

9. The use of any one of claims 1-8 wherein the pirfenidone is to be administered at a total daily dosage of about 1800 mg.

10. The use of any one of claims 1-8 wherein the pirfenidone is to be administered at a total daily dosage of about 2400 mg, preferably 2403 mg.

11. The use of any one of claims 1-8 wherein the CYP1A2 inhibitor is fluvoxamine.

12. The use of any one of claims 1-8 wherein the CYP1A2 inhibitor is enoxacin.

13. The use of any one of claims 1-8 wherein the CYP1A2 inhibitor is ciprofloxacin, amiodarone or propafenone.

14. The use of claim 1(d) wherein the dose of pirfenidone is reduced in a patient receiving a strong inhibitor of CYP1A2.

15. The use of claim 1(d) characterized in that the dose of pirfenidone is reduced to a total daily dose of 801 mg/day in the patient receiving a strong inhibitor of CYP1A2.

16. The use of any one of claims 14-15 wherein the strong inhibitor of CYP1A2 is fluvoxamine.

17. The use of any one of claims 14-15 wherein the strong inhibitor of CYP1A2 is enoxacin.

18. The use of any one of claims 1-17 wherein the patient has idiopathic pulmonary fibrosis (IPF).

19. The use of any of claims 1-17 wherein the patient suffers from a disease selected from idiopathic pulmonary fibrosis, pulmonary fibrosis, idiopathic interstitial pneumonia,

myocardiac fibrosis, musculoskeletal fibrosis, fibrotic vascular disease, scleroderma, Hermansky-Pudlak syndrome, neurofibromatosis, lymph node fibrosis associated with HIV, inflammatory pulmonary fibrosis, pancreatic fibrosis, hepatic fibrosis, or renal fibrosis.

20. The use of any one of claims 1-17 wherein the patient is in need of an anti-fibrotic agent.

21. The use of any one of claims 1-17 wherein the patient has pulmonary fibrosis, myocardiac fibrosis, musculoskeletal fibrosis, pancreatic fibrosis, hepatic fibrosis, renal fibrosis, fibrotic vascular disease or scleroderma.

22. The use of any one of claims 1-21 wherein pirfenidone is to be administered to the patient three times per day, with food.

23. A package or kit for use in treating a patient in need of pirfenidone therapy, comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling comprising avoiding or discontinuing or contraindicating concomitant use of or co-administration of (1) a strong inhibitor of CYP1A2, or (2) a moderate to strong inhibitor of both (i) CYP1A2 and (ii) another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1, or (3) a CYP1A2 inhibitor selected from the group consisting of fluvoxamine, enoxacin, ciprofloxacin, amiodarone and propafenone in patients receiving pirfenidone, wherein the patient is in need of therapy with a CYP1A2 inhibitor.